Published in J Diabetes Sci Technol on May 01, 2007
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (2007) 4.47
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring) (2007) 2.68
Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc (1999) 2.15
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res (2003) 1.59
Prevalence of obesity in dogs examined by Australian veterinary practices and the risk factors involved. Vet Rec (2005) 1.56
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets (2007) 1.15
Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA (1993) 0.97
Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull (2005) 0.92
Performance-enhancing substances: what athletes are using. Cleve Clin J Med (2001) 0.80
Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med (2013) 6.64
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther (2012) 2.46
The missing element of telemedicine for diabetes: decision support software. J Diabetes Sci Technol (2009) 1.83
Time synching or time sinking? Diabetes Technol Ther (2005) 1.70
The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges. Diabetes Care (2004) 1.55
Using telemedicine to improve outcomes in diabetes--an emerging technology. J Diabetes Sci Technol (2009) 1.52
Blood glucose meter market: this world is undergoing drastic changes. J Diabetes Sci Technol (2013) 1.51
Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci Technol (2010) 1.48
Technical aspects of the Parkes error grid. J Diabetes Sci Technol (2013) 1.41
Second insulin pump safety meeting: summary report. J Diabetes Sci Technol (2010) 1.40
A review of the security of insulin pump infusion systems. J Diabetes Sci Technol (2011) 1.34
Regulatory controversies surround blood glucose monitoring devices. J Diabetes Sci Technol (2010) 1.32
New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes-when this practice is not applied properly. J Diabetes Sci Technol (2008) 1.15
The need for clinical accuracy guidelines for blood glucose monitors. J Diabetes Sci Technol (2012) 1.14
Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical? Diabetes Care (2003) 1.11
Personalized medicine for diabetes. J Diabetes Sci Technol (2008) 1.05
SMBG out of control: the need for educating patients about control solution. Diabetes Educ (2013) 0.99
Designing an artificial pancreas system to be compatible with other medical devices. J Diabetes Sci Technol (2008) 0.99
The current status of bolus calculator decision-support software. J Diabetes Sci Technol (2012) 0.97
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol (2013) 0.97
Technology to treat hyperglycemia in trauma. J Diabetes Sci Technol (2007) 0.94
Subcutaneous continuous glucose monitoring in severe burn patients. Crit Care Med (2007) 0.92
Quality Control of Insulins and Biosimilar Insulins: What Do We Know? J Diabetes Sci Technol (2016) 0.91
Point-of-Care Blood Glucose Meter Accuracy in the Hospital Setting. Diabetes Spectr (2014) 0.90
Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther (2014) 0.90
Improved outcomes from diabetes monitoring: the benefits of better adherence, therapy adjustments, patient education, and telemedicine support. J Diabetes Sci Technol (2012) 0.89
Twelve modern digital technologies that are transforming decision making for diabetes and all areas of health care. J Diabetes Sci Technol (2013) 0.88
Improving the safety of blood glucose monitoring. J Diabetes Sci Technol (2011) 0.86
The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol (2011) 0.86
Spending for diabetes drugs is increasing in the United States. J Diabetes Sci Technol (2008) 0.81
The increasing incidence of diabetes in the 21st century. J Diabetes Sci Technol (2009) 0.80
United Kingdom prospective diabetes study follow-up studies establish a legacy effect of therapy for hyperglycemia but not hypertension. J Diabetes Sci Technol (2008) 0.79
The need for performance standards for continuous glucose monitors. J Diabetes Sci Technol (2007) 0.78
The need for a glycemia modeling comparison workshop to facilitate development of an artificial pancreas. J Diabetes Sci Technol (2010) 0.78
A sweetened beverage tax is needed to combat the obesity epidemicas well as related absenteeism and presenteeism. J Diabetes Sci Technol (2009) 0.78
Hospital diabetes: why quality of care matters to both patients and hospitals. J Diabetes Sci Technol (2011) 0.78
The benefits of implanted glucose sensors. J Diabetes Sci Technol (2007) 0.78
The beneficial effects of a Paleolithic diet on type 2 diabetes and other risk factors for cardiovascular disease. J Diabetes Sci Technol (2009) 0.77
Microdialysis of interstitial fluid for continuous glucose measurement. Diabetes Technol Ther (2003) 0.76
Business and economics of diabetes. J Diabetes Sci Technol (2008) 0.76
Glutamic Acid decarboxylase therapy for recent-onset type 1 diabetes: are we at the end or the beginning of finding a cure? J Diabetes Sci Technol (2009) 0.75
Fibroblast growth factor: will this hormone be the hemoglobin A1c for managing phosphorus balance in chronic kidney disease? J Diabetes Sci Technol (2010) 0.75
Bariatric surgery for obese adolescents. J Diabetes Sci Technol (2007) 0.75
The "catalyst to better diabetes care act of 2007". J Diabetes Sci Technol (2008) 0.75
The link between diabetes, military metabolic monitoring, and NASA. Diabetes Technol Ther (2003) 0.75
Freedom of speech and science: can companies force us to withdraw data they don't like? J Diabetes Sci Technol (2013) 0.75
Pyruvate therapy for severe hypoglycemia. Diabetes Technol Ther (2005) 0.75
European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools. Diabetes Technol Ther (2002) 0.75
Current, emerging, and future trends in metabolic monitoring. Diabetes Technol Ther (2002) 0.75
The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes. Diabetes Technol Ther (2002) 0.75
An adaptive drug infusion system. Diabetes Technol Ther (2004) 0.75
The new food and drug administration center for devices and radiological health engineering and physics laboratory and methods for testing software that controls infusion pumps. J Diabetes Sci Technol (2007) 0.75
Technology for portable measurement of blood lactate. Diabetes Technol Ther (2003) 0.75